Clinical Trials Logo

Glabellar Frown Lines clinical trials

View clinical trials related to Glabellar Frown Lines.

Filter by:

NCT ID: NCT05059587 Completed - Clinical trials for Glabellar Frown Lines

Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines

Start date: August 30, 2021
Phase: Phase 3
Study type: Interventional

This study is intended to evaluate the efficacy and safety of MBA-P01 compared to BOTOX in treatment of glabellar lines.

NCT ID: NCT04996810 Completed - Clinical trials for Glabellar Frown Lines

The Safety and Efficacy Study of PROTOXIN in Subjects With Moderate to Severe Glabellar Lines

Start date: December 10, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study will be conducted in Phase I/II clinical trials. In Phase I, subjects with moderate to severe glabellar lines are enrolled and those who are judged to be eligible for this study will be injected with the "PROTOXIN" at a total of 20U(4U/0.1mL each) in five sites of the glabellar lines. Safety is assessed after 12 weeks. In Phase II, subjects with moderate to severe glabellar lines are enrolled and will be injected the "PROTOXIN" or the "BOTOX®" at a total of 20U(4U/0.1mL each)in five sites of the glabellar lines. Thereafter, efficacy and safety are assessed by comparing with BOTOX®.

NCT ID: NCT04830345 Completed - Clinical trials for Glabellar Frown Lines

Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines

Start date: June 29, 2020
Phase: Phase 3
Study type: Interventional

Efficacy and safety of ATGC-100 are assessed in subjects with moderate to severe glabellar lines.

NCT ID: NCT04281095 Completed - Clinical trials for Glabellar Frown Lines

A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines

Start date: November 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Efficacy and safety of the investigational product, ATGC-110, was evaluated in comparison with Botox for a total of 12 weeks after the administration in treatment of glabellar frown lines.

NCT ID: NCT04249583 Completed - Clinical trials for Glabellar Frown Lines

Treatment of Moderate to Severe Glabellar Lines

READY-1
Start date: February 10, 2020
Phase: Phase 3
Study type: Interventional

The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe GL.

NCT ID: NCT04143815 Completed - Clinical trials for Glabellar Frown Lines

Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines

Start date: May 20, 2019
Phase: Phase 2
Study type: Interventional

This study will determine the effect of MBA-P01 in subjects with glabellar lines at a range of doses compared with placebo. This study includes two treatment period; 1) Dose-ranging period, Day0 to 16weeks and 2) Open-label extension period, 16 weeks to 52.

NCT ID: NCT03985982 Completed - Clinical trials for Glabellar Frown Lines

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)

BLESSIII
Start date: April 29, 2019
Phase: Phase 3
Study type: Interventional

The aim of this study is to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo, including efficacy after repeat treatments and long term safety.

NCT ID: NCT03960957 Completed - Clinical trials for Glabellar Frown Lines

Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines

Start date: June 17, 2019
Phase: Phase 3
Study type: Interventional

An interventional phase 3 study to evaluate efficacy and safety of a new dilution and injection volume of AbobotulinumtoxinA treatment for glabellar lines

NCT ID: NCT03908008 Completed - Clinical trials for Glabellar Frown Lines

Efficacy and Safety Study of MT10107 in the Treatment of Glabella Line

Start date: January 2014
Phase: Phase 3
Study type: Interventional

This study design is a parallel, active drug controlled, double blind, randomized, multi-centered, phase III clinical trial to compare the efficacy and safety of MT10107 versus BOTOX® in treatment of glabella line.

NCT ID: NCT03837561 Completed - Clinical trials for Glabellar Frown Lines

The Efficacy and Safety of CUNOX® in Patients With Moderate to Severe Glabellar Lines

Start date: December 13, 2018
Phase: Phase 3
Study type: Interventional

To Confirm the non-inferiority of CUNOX® to BOTOX® in the glabellar line improvement of moderate to severe glabellar lines.